Scancell Holdings (LON:SCLP) has signed its first deal with an unnamed antibody technology company to develop an early-stage technology created to kill tumour cells directly.
CEO Cliff Holloway tells Proactive London why this is significant and details how it complements Scancell's existing antibody technology.
News here too on what is unique about Scancell's antibody pipeline.